Nazol N (Xylometazoline Hydrochloride)

Xylometazoline is an alpha‑adrenergic nasal decongestant that reduces swelling of the nasal mucosa in various upper‑respiratory conditions.

• Nasal congestion: provides rapid relief of blocked nasal passages by constricting dilated vessels and decreasing mucosal edema.
• Allergic rhinitis: alleviates nasal blockage and improves airflow during seasonal or perennial allergic episodes.
• Non‑allergic rhinitis: reduces congestion associated with irritant‑induced or vasomotor rhinitis, enhancing breathing comfort.

• Xylometazoline Hydrochloride acts as a selective alpha‑adrenergic receptor agonist on the smooth muscle of nasal mucosal blood vessels. Activation of α1‑adrenergic receptors induces vasoconstriction, which diminishes blood flow to the nasal submucosa, leading to reduced edema and opening of the nasal airway. The localized effect limits systemic absorption, providing fast and rapid therapeutic onset of decongestion with minimal systemic activity.

Xylometazoline nasal spray may cause local and systemic adverse reactions, most of which are mild and transient.

Common Side Effects

• Nasal burning or stinging: a transient irritation at the site of application that usually resolves within minutes.
• Dryness of the nasal passages: reduced moisture leading to a feeling of dryness or crusting inside the nose.
• Sneezing: an immediate reflex response that may occur shortly after spray administration.

Serious or Rare Side Effects

• Hypertension or increased blood pressure: systemic vasoconstriction can raise arterial pressure, especially in patients with pre‑existing cardiovascular disease.
• Severe allergic reaction (anaphylaxis, angioedema): rare but potentially life‑threatening hypersensitivity requiring immediate medical attention.
• Rebound congestion or nasal septum perforation with prolonged use: chronic application beyond recommended duration may cause persistent blockage or tissue damage.

When using Nazol N, several safety considerations should be observed to minimize risks and ensure effective treatment.

• Duration of use: limit administration to no more than 3‑5 consecutive days to avoid rebound congestion.
• Age restriction: avoid use in children under 6 years unless directed by a healthcare professional.
• Cardiovascular conditions: do not use if you have uncontrolled hypertension, coronary artery disease, or severe heart disease.
• Concomitant decongestants: avoid simultaneous use of other nasal or systemic decongestants to prevent excessive vasoconstriction.
• Pregnancy and lactation: consult a physician before use, as safety data are limited.
• Store at room temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Xylometazoline may interact with certain medicines, altering its effects or increasing the risk of adverse events.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): combined use can cause excessive vasoconstriction and hypertensive crisis.
• Other nasal decongestants (e.g., phenylephrine, oxymetazoline): additive vasoconstrictive effect may raise blood pressure.
• Systemic sympathomimetic agents (e.g., pseudoephedrine): increased risk of cardiovascular side effects.

Moderate Interactions (Monitor Closely)

• Antihypertensive drugs (beta‑blockers, ACE inhibitors): may reduce the blood‑pressure‑lowering effect of the medication.
• Tricyclic antidepressants: potential for enhanced vasoconstrictive response.
• Alcohol: may increase dizziness or headache when combined with the spray.